

ForPatients

by Roche

Advanced Solid Tumors Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC)
Non Small Cell Lung Carcinoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Trial Status
Recruiting

Trial Runs In
18 Countries

Trial Identifier
NCT04449874 2020-000084-22,
2023-506311-18-00 GO42144

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT04449874 2020-000084-22, 2023-506311-18-00 GO42144
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
